1
|
Caglevic C, Gallardo J, de la Torre M, Mahave M, Müller B, Solé S, Moscoso Y, De La Fuente H, Roa JC, Hoefler S, Butte JM, González M P, O'Connor JM, Torres J, Pérez Encalada V, Alarcón Cano D, Ubillos L, Rolfo C, Lingua A, Díaz Romero C, Padilla Rosciano A, Cuartero V, Calderillo Ruiz G, Schwartsmann G, Kon Jara X, Andrade G A, Mas López L, Barajas O, Carballido M, Lembach H, Morillas G L, Roca E, Lobatón J, Montenegro B P, Yepes A, Marsiglia H. [Recommendations for the management of pancreatic cancer type adenocarcinoma: A consensus statement reached during the 2015 Latin American Symposium on Gastroenterological Oncology]. Rev Med Chil 2017; 144:1305-1318. [PMID: 28074986 DOI: 10.4067/s0034-98872016001000010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Pancreatic cancer is a malignancy of great impact in developed countries and is having an increasing impact in Latin America. Incidence and mortality rates are similar for this cancer. This is an important reason to offer to the patients the best treatments available. During the Latin American Symposium of Gastroenterology Oncology (SLAGO) held in Viña del Mar, Chile, in April 2015, a multidisciplinary group of specialists in the field met to discuss about this disease. The main conclusions of this meeting, where practitioners from most of Latin American countries participated, are listed in this consensus that seek to serve as a guide for better decision making for patients with pancreatic cancer in Latin America.
Collapse
Affiliation(s)
| | | | - Marcela de la Torre
- Centro Especializado en Terapia Radiante, Hospital Clínicas San José de San Martín, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Mauricio Mahave
- Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile,
| | | | | | - Yuri Moscoso
- Unidad de Cuidados Paliativos, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
| | | | | | | | - Jean M Butte
- Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile
| | | | - Juan Manuel O'Connor
- Sección de Tumores Gastrointestinales, Instituto Alexander Fleming, Buenos Aires, Argentina
| | - Javiera Torres
- Pontificia Universidad Católica de Chile, Santiago, Chile
| | | | | | - Luis Ubillos
- Servicio de Oncología Clínica, Hospital de Clínicas, Montevideo, Uruguay
| | - Christian Rolfo
- Unidad de Desarrollo Temprano de Drogas-Estudios Fase I, Hospital Universitario de Antwerp, Amberes, Bélgica
| | - Alejo Lingua
- Área Oncología Digestiva, Clínica Privada Universitaria Reina Fabiola, Córdoba, Argentina
| | - Consuelo Díaz Romero
- Unidad Funcional de Tumores Digestivos, Instituto Nacional de Cancerología, México, México
| | | | | | | | | | | | | | - Luis Mas López
- Instituto Nacional de Enfermedades Neoplásicas,Lima,Perú
| | - Olga Barajas
- Instituto Oncológico Fundación Arturo López Pérez,Santiago,Chile
| | - Marcela Carballido
- Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo,Buenos Aires,Argentina
| | | | - Lena Morillas G
- Centro de Enfermedades Neoplásicas ONCOVIDA, La Paz, Bolivia
| | - Enrique Roca
- Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo,Buenos Aires,Argentina
| | | | | | - Andrés Yepes
- Fundación Colombiana de Cancerología, Medellín,Colombia
| | - Hugo Marsiglia
- nstituto Oncológico Fundación Arturo López Pérez,Santiago,Chile
| |
Collapse
|